Our website uses cookies to distinguish you from other users of our site. This helps us to continually improve your experience when using our website. We also use external analytics software which may set additional cookies to perform their analysis. These cookies (and any others in use) are detailed in our site Privacy and Cookie Policies. You can delete or disable these cookies in your web browser at any time but doing so may impact website functionality and user experience.


Our Investment Committee

Our Investment Committee makes investment decisions regarding University spin-outs on behalf of our Seed Funds team.

Drawing on the expertise of the Cambridge Cluster, the committee is experienced in all things commercial. It is currently comprised of 15 members.

Investment Committee members

John Lee (Chair)

John was CFO of DisplayLink Corp, a market-leading USB graphics software and semiconductor business, from 2011-20, when it was acquired by Synaptics In. He has been actively involved in the Cambridge technology scene for over 35 years and has held senior management roles and/or been an investor in a number of start-ups, many of which have resulted in successful exits or IPOs. Previously, John was CEO of Velocix, a leading provider of content delivery network solutions, and successfully exited the business to Alcatel-Lucent.

Dr Keith Blundy

Keith is the CEO of the Cambridge cancer drug discovery start-up Storm Therapeutics and the former CEO of Cancer Research Technology (CRT). His experience covers 10 years developing and commercialising plant biotechnology inventions and the last 20 years in cancer drug discovery and IP commercialisation. While at CRT he established the CRT Pioneer Fund and was involved in forming companies such as Kudos, PIramed, Mission Therapeutics and GammaDelta Therapeutics and Inivata. He has a PhD from the John Innes Institute (UEA) and an MBA from London Business School.

Charles Cotton

Charles founded The Cambridge Phenomenon Ltd and has co-written two books about the Cambridge cluster of hi-tech companies. He enjoys science and technology, helping to build global scale companies and developing technology clusters.

Dr Barbara Domayne-Hayman

Barbara has a broad range of commercial, fund-raising and general management experience, with many years of business development in the biotech sector. She is currently Chief Business Officer at Autifony Therapeutics and Entrepreneur-in-Residence at the Francis Crick Institute, where she helps run the KQ Labs accelerator for data-driven health start-ups. She also chairs the LifeArc Seed Fund Investment Committee. She has a BA and DPhil in chemistry from the University of Oxford and holds a Sloan Fellowship from London Business School.

Pam Garside

Pam is an adviser in health care systems and digital health working in the UK and USA. She is a Fellow of the Judge Business School at the University and an angel investor in health technology start-ups. She sits on a number of boards, including Cambridge Angels and Crown Place VCT, and also advises health technology accelerators in the UK.

Dr Iris Good

Specialising in medical devices, Iris has been involved in technology innovation, commercialisation and market expansion to India for two decades. She co-founded UltraShape, acquired in 2012, and opened MetaCure’s Indian operations. Iris chairs Good Relations India (GRI), a market entry and positioning advisory, which brought to India companies such as M&S, SunLife, Virgin Atlantic, Apple and numerous tech start-ups. She is Chairman of London Business School HealthTech Challenge and of Imperial College Seed Fund.

John Halfpenny

John has a successful track record as a Director and CXO of high tech and clean tech companies, having grown and sold several start-ups. He was responsible for CMR Fuel Cells’ London Stock Exchange AIM listing, and was Director of Embedded Software at ARM plc. John founded and sold Micrologic Solutions to ARM plc and has negotiated IP licensing, outsourced manufacturing, distributor and JV agreements globally. John has a Masters’ degree in Engineering Science from the University of Cambridge and is a Fellow of The Institution of Engineering and Technology.

Andrew Herbert

Andrew is a computer systems engineer and entrepreneur. He is the former director of the Microsoft Research laboratory in Cambridge.

Dr Richard Jennings

Richard was Deputy Director of Cambridge Enterprise and obtained funding for and established the first seed fund, the Challenge Fund. He has a substantial track record in spinning out companies, including Solexa, Entropic and Kudos, and technology licensing, as well as establishing consultancy and collaborative projects with industry. He has extensive board experience of early stage companies.

Derek Jones

Derek has over 25 years’ experience in the life-science sector. He is currently the CEO at the Babraham Research Campus, one of the UK’s leading campuses to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the Babraham Institute. He is also a non-executive Director at Rothamsted Enterprises, and a Fellow at Lucy Cavendish College at the University of Cambridge.

Professor Patrick Maxwell

Patrick is a clinician scientist and in 2012 was appointed Regius Professor of Physic and Head of the School of Clinical Medicine at the University of Cambridge. He is also a Director of Cambridge University Health Partners, the Academic Health Sciences Centre for Cambridge. Patrick has been centrally involved in a series of discoveries that have revealed how changes in oxygenation are sensed, and how genetic alterations cause kidney disease. He currently holds a Wellcome Trust Senior Investigator Award and is an NIHR Senior Investigator Emeritus. He has a research group in the Cambridge Institute for Medical Research. Patrick is a Fellow of the Royal College of Physicians and the Academy of Medical Sciences.

Dr Tony Raven (Chief Executive Officer, Cambridge Enterprise)

Tony joined Cambridge Enterprise as Chief Executive in December 2011. Previously he was Director of Research & Innovation Services at the University of Southampton, where he helped establish Southampton’s international reputation as a leading entrepreneurial university, creating a portfolio of 11 spin-out companies with four listings on the London Stock Exchange.

Heather Richards

Heather has a broad range of experience encompassing fundraising, marketing, product strategy and business management. As CEO of Transversal, a Cambridge-based tech company, she was instrumental in its journey from start-up to acquisition by Verint Systems in 2019. She is currently VP of Product Strategy and GTM at Verint, responsible for driving the global strategy for their Knowledge Management portfolio. Heather has an MPhil from Cambridge University in European Literature.

Andy Sandham

Andrew has more than 30 years’ experience in co-founding and building start-up businesses in the biotechnology sector in the UK and USA. He has served in chairman, non-executive and executive roles with UK and US biotech start-up companies, including Celltech, Cantab Pharmaceuticals, Hexagen, Signature Bioscience, Novacta, Ionix Pharmaceuticals, NeurAxon, Syntaxin, Synosia, Kymab, Bicycle Therapeutics and 14M Genomics. He has also worked within venture capital firms Abingworth and Syncona and currently serves as Chairman of PredictImmune, PolyProx Therapeutics and LoQus23 Therapeutics.

Dr Paul Seabright (Deputy Directory, Cambridge Enterprise)

Paul first joined Cambridge Enterprise in 2001 and returned after he completed his time with Health Enterprise East in 2009. Paul has considerable experience of technology transfer in both the biotech and medtech sectors.

Professor Steve Young

Steve is Emeritus Professor in Information Engineering and former Senior ProVice Chancellor. He is expert in spoken language systems, conversational AI and machine learning. He has been involved in a number of successful Cambridge spin-outs including Entropic, Phonetic Arts and VocalIQ.